Skip to main content

Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

Terminated · Not applicable · NCT06455475

Conditions: Diabetic Foot Ulcer

At a glance

Research payments reported, 2025
$816,982
U.S. investigators named
15
Sites paid
15
Planned or actual enrollment
120

About the trial

Sponsor
Capsicure, LLC
Tested
Derm-Maxx (other)
Dates
Started 2024-10-25; completion 2026-05-22
Results posted
Not yet

This randomized controlled study evaluates the adjuvant use of Derm-Maxx in patients with diabetic foot ulcers

From ClinicalTrials.gov, last updated 2026-05-28. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Royal Biologics, Inc. reported $816,982 in research payments for this study in 2025 (101 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Cole Collaborative Consulting, LLC $180,000
  • Dp Bell Consulting, LLC $120,000
  • Royal Research Corp $103,470
  • Royal Research South $87,375
  • Alloy Clinical Research $53,830
  • Premium Podiatry Corp $45,680
  • Bioresearch PArtner $45,585
  • Wahab Consulting and Research $41,805
  • C7 Research $37,077
  • Nar Medical Research $36,885
  • Abc Podiatry $23,920
  • Olympus Clinical Research $17,705
  • Kent State University $16,850
  • Statera Research $6,300
  • Bioresearch PArtner Miami Lakes $500

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.